Elraglusib

What is Elraglusib?

Elraglusib is a maleimide-based small molecule inhibitor of glycogen synthase kinase-3 (GSK-3). It binds to and competitively inhibits GSK-3, leading to downregulation of NF-kappaB signaling and decreased expression of anti-apoptotic proteins. The drug is studied in various cancers including pancreatic cancer, sarcoma, renal cancer, non-Hodgkin lymphoma, breast, lung, and colorectal cancers.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as

9-ING-41

Drug type

Small molecule

Targets

glycogen synthase kinase-3 (GSK3B)

Mechanism

Inhibitor of glycogen synthase kinase-3 (GSK3B)

Pathways

NF-kappaB signaling, protein synthesis, cellular proliferation, apoptosis

Therapy area

Oncology

Developer

Actuate Therapeutics Inc. (ACTU)

FDA status

Investigational, not approved in the US. Most advanced trial: Phase 2

UNII

ND1SOF0DLU

🧪 Clinical trials

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

CancerNeoplasm MetastasisNeoplasm of BoneNeoplasm of LungNeoplasm, BreastNeoplasms PancreaticNeoplasms,ColorectalPancreatic AdenocarcinomaPancreatic CancerRefractory CancerRefractory NeoplasmRefractory Non-Hodgkin LymphomaRenal CancerResistant Cancer

Sources

• NCI Thesaurus
• ClinicalTrials.gov NCT03678883
• ClinicalTrials.gov NCT07714395

Updated Oct 3, 2026. Something wrong or missing? Report it on the ACTU page.